ATE28566T1 - Zellgiftiges arzneimittel enthaltend mindestens ein immunotoxin und ein amin. - Google Patents

Zellgiftiges arzneimittel enthaltend mindestens ein immunotoxin und ein amin.

Info

Publication number
ATE28566T1
ATE28566T1 AT83400458T AT83400458T ATE28566T1 AT E28566 T1 ATE28566 T1 AT E28566T1 AT 83400458 T AT83400458 T AT 83400458T AT 83400458 T AT83400458 T AT 83400458T AT E28566 T1 ATE28566 T1 AT E28566T1
Authority
AT
Austria
Prior art keywords
amine
immunotoxin
cell
pct
product containing
Prior art date
Application number
AT83400458T
Other languages
English (en)
Inventor
Franz Jansen
Pierre Gros
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Application granted granted Critical
Publication of ATE28566T1 publication Critical patent/ATE28566T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT83400458T 1982-03-11 1983-03-07 Zellgiftiges arzneimittel enthaltend mindestens ein immunotoxin und ein amin. ATE28566T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8204119A FR2536997B1 (fr) 1982-03-11 1982-03-11 Medicaments cytotoxiques comportant au moins une immunotoxine et de la methylamine
EP83400458A EP0089270B1 (de) 1982-03-11 1983-03-07 Zellgiftiges Arzneimittel enthaltend mindestens ein Immunotoxin und ein Amin

Publications (1)

Publication Number Publication Date
ATE28566T1 true ATE28566T1 (de) 1987-08-15

Family

ID=9271880

Family Applications (1)

Application Number Title Priority Date Filing Date
AT83400458T ATE28566T1 (de) 1982-03-11 1983-03-07 Zellgiftiges arzneimittel enthaltend mindestens ein immunotoxin und ein amin.

Country Status (7)

Country Link
US (1) US4614650A (de)
EP (1) EP0089270B1 (de)
JP (1) JPS59500371A (de)
AT (1) ATE28566T1 (de)
DE (1) DE3372708D1 (de)
FR (1) FR2536997B1 (de)
WO (1) WO1983003200A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2516794B1 (fr) * 1981-11-20 1985-10-25 Sanofi Sa Nouveaux medicaments anticancereux pour le traitement des leucemies t constitues de la chaine a de la ricine et d'un anticorps monoclonal specifique
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
FR2573656B1 (fr) * 1984-11-29 1987-02-27 Sanofi Sa Medicament comportant en tant qu'association au moins une immunotoxine et au moins un polymere contenant du mannose
US4689401A (en) * 1986-03-06 1987-08-25 Cetus Corporation Method of recovering microbially produced recombinant ricin toxin a chain
JP2006100141A (ja) * 2004-09-29 2006-04-13 Toshiba Corp 付臭剤、燃料電池用液体燃料及び燃料電池
GB0507672D0 (en) * 2005-04-15 2005-05-25 Barnaba Vincenzo Adjuvant
JP4444355B2 (ja) * 2008-09-03 2010-03-31 株式会社東芝 燃料電池

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2466252A2 (fr) * 1979-10-03 1981-04-10 Clin Midy Nouveaux produits ayant notamment des proprietes anticancereuses a base de chaine a de la ricine et d'une proteine
JPS57197223A (en) * 1981-05-27 1982-12-03 Eisai Co Ltd Immunoenhancing agent containing ricin b chain
US4489710A (en) * 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
FR2516794B1 (fr) * 1981-11-20 1985-10-25 Sanofi Sa Nouveaux medicaments anticancereux pour le traitement des leucemies t constitues de la chaine a de la ricine et d'un anticorps monoclonal specifique
US4485093A (en) * 1982-08-13 1984-11-27 Runge Richard G Immunotoxin conjugate which comprises arsanilic acid, useful for treating malignant tumors, particularly pancreatic cancer

Also Published As

Publication number Publication date
WO1983003200A1 (en) 1983-09-29
JPS59500371A (ja) 1984-03-08
US4614650A (en) 1986-09-30
EP0089270A1 (de) 1983-09-21
DE3372708D1 (en) 1987-09-03
EP0089270B1 (de) 1987-07-29
FR2536997A1 (fr) 1984-06-08
FR2536997B1 (fr) 1987-08-07
JPH0455173B2 (de) 1992-09-02

Similar Documents

Publication Publication Date Title
IE862554L (en) Pharmaceutical compositions
ATE2667T1 (de) Antidepressiv wirkende derivate des trans-4phenyl-1,2,3,4-tetrahydro-1-naphthalin-amins und pharmazeutische zusammensetzungen daraus.
GR3017282T3 (en) Novel arylpyridazines, their manufacture, use and medicaments containing them.
SE8700499D0 (sv) Novel pharmacologically active compounds
PL297399A1 (en) Masked taste pharmaceutical preparations
CY2123B1 (en) Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides drugs containing these compounds and use of such drugs
TW272195B (de)
FR2677984B1 (fr) Derives d'imidazoline n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
IT1212778B (it) Composizioni farmaceutiche adattivita' antiinfiammatoria e/o analgesica, non ulcerogene.
RU92016463A (ru) Применение производных цистина для изготовления лекарственных препаратов с иммуномоделирующим действием, фармацевтические композиции на их основе
FI972308A (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
ATE28566T1 (de) Zellgiftiges arzneimittel enthaltend mindestens ein immunotoxin und ein amin.
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
MY114282A (en) Anthracycline derivatives
DK0443848T3 (da) Nyt antiulcermiddel
IL67940A0 (en) 2,3-diaryl-5-halo-thiophenes,their preparation and pharmaceutical compositions containing them
DE68920896T2 (de) N2-(1-Carboxy-3-phenylpropyl)-L-lysinderivate und Verfahren für die Herstellung von Lysinopril mit Hilfe dieser Verbindung.
EP0515995A3 (en) N-(5-thioxo-l-prolyl)-l-cysteine, derivatives thereof, processes for the preparation thereof and pharmaceutical compositions containing them
MX9203361A (es) Composiciones farmaceuticas que contienen cloruro de galio.
ATE20519T1 (de) Zellgiftiges arzneimittel enthaltend mindestens ein immunotoxin und chloroquin.
ZA81927B (en) Phenylpiperazine derivatives of 1,3,4-oxadiazolyphenols their preparation and therapeutic agents containing these compounds
IL97321A0 (en) Diamine derivatives,their manufacture and pharmaceutical compositions containing them
SE8105500L (sv) Psykotropa lekemedel
NZ268476A (en) 14-substituted marcfortines, preparation and pharmaceutical compositions thereof
ATE6124T1 (de) Arzneimittel zur lokalen behandlung des glaukoms.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee